MREO earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -1.33. Updated 2026-07-23.
Mereo BioPharma Group (MREO) Research Hub
Mereo BioPharma Group (MREO) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.28 USD (+15.46%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.33, market cap 0.05B. This hub links to the full technical, earnings and options research available for MREO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 0.28 USD (+15.46%) |
| 52-week range | 0.2385 USD – 0.3695 USD |
| Trend regime | Range |
| 14-day RSI | 45.5 (Neutral) |
| Trailing P/E | -1.33 |
| Market cap | 0.05B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for MREO
Covered Call on MREO: how it works, illustrative setup around the real 0.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MREO: how it works, illustrative setup around the real 0.28 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MREO: how it works, illustrative setup around the real 0.28 USD price, max profit/loss, breakeven and when to use it. Educational.
MREO technical analysis: range, last 0.28 USD, RSI 45.5, 52w range 0.2385 USD–0.3695 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MREO in?
Mereo BioPharma Group (MREO) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is MREO in an uptrend or downtrend?
As of 2026-09-11, MREO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MREO's trailing P/E ratio?
MREO's trailing P/E is -1.33, with a market cap of 0.05B. See the earnings research page for full valuation detail.
When does MREO next report earnings?
MREO is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.01 USD.